interactive response technology

R&D

Revolutionising personalised medicine: How IRT platforms are...

Cell and gene therapies offers transformative benefits to patients, including revolutionary treatment potential for cancer, AIDS, and hereditary diseases.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

interactive response technology

Editor's Picks